Metraipolis › archive › dc_ce7976f05609

Incidence of hematologic malignancies and mortality associated with GLP-1 receptor agonist and SGLT2 inhibitor use in type 2 diabetes mellitus: results of a… — Europe PMC PMID:41583363

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41583363
DOI
10.1016/j.eclinm.2025.103749
License (as archived)
solo-consultazione
Archived
2026-11-06T19:45:44.603Z
SHA-256 of the archived text
2f3088ef9015aa2c17b0f219abab178d6c8433e81d173b3d7979d61a802a561b
Stable URL of this page
https://metraipolis.com/documento/dc_ce7976f05609

How to cite

Incidence of hematologic malignancies and mortality associated with GLP-1 receptor agonist and SGLT2 inhibitor use in type 2 diabetes mellitus: results of a… — Europe PMC PMID:41583363 — Europe PMC (en), https://europepmc.org/article/MED/41583363 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_ce7976f05609 (Metraipolis archive dc_ce7976f05609, sha256 2f3088ef9015aa2c17b0f219abab178d6c8433e81d173b3d7979d61a802a561b)
BibTeX
@misc{dcce7976f05609,
  title = {Incidence of hematologic malignancies and mortality associated with GLP-1 receptor agonist and SGLT2 inhibitor use in type 2 diabetes mellitus: results of a… — Europe PMC PMID:41583363},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41583363},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_ce7976f05609; sha256 2f3088ef9015aa2c17b0f219abab178d6c8433e81d173b3d7979d61a802a561b},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41583363. Agents can read the archived copy with the MCP tool read_document.